Jason A. Chesney, MD, PhD of the James Graham Brown Cancer Center discusses the impact of the talimogene laherparepvec and ipilimumab combination in melanoma. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract 9509: Primary results from a randomized (1:1), open-label phase II study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected stage IIIB- IV melanoma
Advertisement